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Daptomycin but not Mitomycin C in
Combination with Doxycycline and
Cefuroxime
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Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University,
Baltimore, MD, USA
Lyme disease, caused by Borrelia burgdorferi, is the most common vector-borne
disease in the United States and Europe. While the majority of Lyme disease patients
can resolve their symptoms if treated promptly, 10–20% of patients suffer from
prolonged symptoms called post-treatment Lyme disease syndrome (PTLDS). Although
the cause for PTLDS is unclear, one possibility is the presence of bacterial persisters
not effectively cleared by the current Lyme antibiotics. Recent studies identified several
drug candidates including daptomycin, daunomycin, doxorubicin, and mitomycin C that
had good activity against B. burgdorferi persisters. However, their relative activities
against B. burgdorferi persisters have not been evaluated under the same conditions.
In this study, we tested the anti-persister activities of these drugs against both 7-day
and 15-day old stationary phase cultures of B. burgdorferi individually as well as in
combination with Lyme antibiotics doxycycline and cefuroxime (Ceftin). Our findings
demonstrate daunomycin and daptomycin were more active than mitomycin C in single
drug comparison at 10 and 20 µM, as well as in drug combinations with doxycycline and
cefuroxime. In addition, daunomycin was more active than doxorubicin which correlated
with their ability to stain and accumulate in B. burgdorferi. The two drug combination
of doxycycline and cefuroxime was unable to eradicate biofilm-like microcolonies of
B. burgdorferi persisters. However, the addition of either daunomycin or daptomycin
to the doxycycline + cefuroxime combination completely eradicated the biofilm-like
structures and produced no visible bacterial regrowth after 7 and 21 days, while the
addition of doxorubicin was unable to prevent regrowth at either 7 or 21 day subculture.
Mitomycin C in combination with doxycycline and cefuroxime caused no regrowth at
7 days but visible spirochetal regrowth occurred after 21 day subculture. Furthermore,
we found that cefuroxime (Ceftin), the third commonly used and most active antibiotic
to treat Lyme disease, could replace cefoperazone (a drug no longer available in the US)
in the daptomycin + doxycycline combination with complete eradication of the biofilm-
like structures as shown by lack of any regrowth in subcultures. Our findings may have
implications for improved treatment of Lyme disease.
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INTRODUCTION
Borrelia burgdorferi is the causative agent of Lyme disease,
which is the most common vector-borne disease in the United
States with an estimated 300,000 cases in 2013(CDC, 2015a).
The infection is transmitted to humans by tick vectors that
feed upon rodents, reptiles, birds and deer (Radolf et al., 2012).
In the early stage of Lyme disease, approximately 50% of
patients have localized erythema migrans, a target-shaped rash
that expands as the bacteria disseminate from the cutaneous
infection site (CDC, 2015a). Late stage Lyme disease is a multi-
system disorder with symptoms including arthritis, carditis, and
neurologic impairment (CDC, 2015a). The majority of Lyme
disease patients can resolve their symptoms if treated promptly
with doxycycline, amoxicillin, or cefuroxime (Wormser et al.,
2006). However, at least 10–20% of Lyme disease patients
experience prolonged symptoms such as neurologic impairment,
muscular pain, and fatigue 6 months after antibiotic treatment,
a collection of symptoms called Post-Treatment Lyme Disease
Syndrome (PTLDS; CDC, 2015b).
The cause of PTLDS is unknown, though there are
several theories including co-infections (Swanson et al., 2006),
autoimmune response (Steere et al., 2001), immune response
to continued presence of antigenic debris (Bockenstedt et al.,
2012), as well as B. burgdorferi persisters that are not killed
by the current antibiotics (Hodzic et al., 2008, 2014; Embers
et al., 2012). Using a combination of diagnostic techniques
including xenodiagnosis and PCR, studies have found evidence of
B. burgdorferi persistence in dogs (Straubinger et al., 1997), mice
(Hodzic et al., 2008, 2014), monkeys (Embers et al., 2012), and
humans (Marques et al., 2014) after antibiotic treatment, though
no viable bacteria could be cultured.
Borrelia burgdorferi develops persisters stochastically in
stationary phase which are tolerant to the antibiotics used to treat
Lyme disease (Feng et al., 2014a, 2015a; Caskey and Embers, 2015;
Sharma et al., 2015). These persister bacteria have been found to
have an altered RNA proﬁle, making them phenotypically drug
tolerant (Feng et al., 2015c). In log phase cultures (3–5 days
old), B. burgdorferi is primarily in motile spirochetal form which
is highly susceptible to current Lyme antibiotics doxycycline
and amoxicillin, however, in stationary phase cultures (7–
15 days old), increased numbers of atypical forms such as round
bodies and aggregated bioﬁlm-like microcolonies develop (Feng
et al., 2014a, 2015a). These atypical forms have been shown to
have increased tolerance to doxycycline and amoxicillin when
compared to the growing spirochetal forms (Feng et al., 2014a,
2015a; Caskey and Embers, 2015; Sharma et al., 2015). Therefore,
stationary phase cultures (7–15 days old) which are enriched in
persisters were used as a model for high-throughput drug screens
against persister populations (Feng et al., 2014a, 2015a,b,d).
Drugs with high activity against the B. burgdorferi stationary
phase persisters were identiﬁed through screens of FDA
approved drug library and NCI compound libraries (Feng
et al., 2014a, 2015b,d). Among them, daptomycin, a lipopeptide
antibiotic targeting bacterial cell membranes, was found from
the FDA drug library to have the highest anti-persister
activity against B. burgdorferi (Feng et al., 2014a). In addition,
anticancer anthracycline antibiotics, such as daunomycin and
doxorubicin, and also mitomycin C were found from the
NCI compound library screen as having excellent or good
activity against B. burgdorferi persisters (Feng et al., 2015b).
Daunomycin, doxorubicin and mitomycin C were all isolated
from Streptomyces and are used in the treatment of a wide
range of cancers. Daunomycin and doxorubicin belong to
anthracycline anti-cancer antibiotic and kill the bacteria by
inhibiting DNA and RNA synthesis, causing DNA damage and
producing reactive oxygen species. Mitomycin C blocks DNA
replication and causes cell death by DNA crosslinking. Although
the anti-persister drugs such as daptomycin are more active than
the current Lyme antibiotics such as doxycycline or amoxicillin
against B. burgdorferi persisters (Feng et al., 2014a ), they alone
could not completely eradicate the more resistant bioﬁlm-like
microcolonies and a drug combination approach is required to
do so (Feng et al., 2015a). The more eﬀective drug combination
approach to eradicate bioﬁlm-like microcolonies is consistent
with the drug combination principle for treatment of persistent
infections like tuberculosis (Zhang et al., 2012; Zhang, 2014).
In a recent study using a relatively young 5 days old culture,
mitomycin C was found to have higher activity than daptomycin
against B. burgdorferi persisters (Sharma et al., 2015). However,
their relative activity against B. burgdorferi persisters has not
been compared or evaluated in the same study under the same
conditions. In this study, four of the identiﬁed drugs with the
highest activity against stationary phase B. burgdorferi persisters
were tested to determine their anti-persister activity at more
clinically achievable levels. In addition, we assessed these persister
active drugs in combination with the commonly prescribed Lyme
antibiotics doxycycline and cefuroxime, which have high activity
against growing log phase cultures, with the aim to increase
the activity of these drugs for more eﬀective treatment of Lyme
disease.
MATERIALS AND METHODS
Strain, Media, and Culture Techniques
Borrelia burgdorferi strain B31 (ATCC 35210) was obtained
from American Type Tissue Collections (Manassas, VA, USA).
B. burgdorferi was grown in BSK-H medium (HiMedia
Laboratories, Mumbai, India) and supplemented with 6% rabbit
serum (Sigma Aldrich, St. Louis, MO, USA). The medium
was ﬁlter-sterilized via passage through a 0.22 µM ﬁlter. The
inoculated medium was incubated in sterile 50 mL conical tubes
(BD Biosciences, San Jose, CA, USA) in a 33◦C incubator without
shaking. The culture was maintained in these conditions for 7 or
15 days until the culture reached stationary phase, when it was
transferred to a 96 well plate for evaluationwith the drugs or their
combinations.
Drugs
The following drugs were obtained from Sigma–Aldrich, St.
Louis, MO, USA and dissolved in the solvents suggested by
the Clinical and Laboratory Standards Institute to make a stock
solution: doxycycline (Dox), cefuroxime (CefU), cefoperazone
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(CefP), daptomycin (Dap), mitomycin C (MitC), doxorubicin
(DoxR), daunomycin (Dau), (Clinical and Laboratory Standards
Institute, 2007). The drug stock solutions were ﬁlter-sterilized
using a 0.22 µM ﬁlter and stored at –20◦C.
Microscopy
The B. burgdorferi cultures were examined using a Zeiss
AxioImager M2 microscope with diﬀerential interference
contrast and epiﬂuorescent illumination. Pictures were taken
using a SPOT slider camera. A SYBR Green I/PI assay was
performed as previously described to assess cell viability using
the ratio of green:red ﬂuorescence to determine the live:dead cell
ratio, respectively, as measured by a plate reader (Feng et al.,
2014b). This residual cell viability reading was conﬁrmed by
analyzing three representative images of the bacterial culture
using epiﬂuorescence microscopy. Image Pro-Plus software was
used to quantitatively determine the ﬂuorescence intensity.
Evaluation of Drugs Against Biofilm-Like
Structures in B. burgdorferi Stationary
Phase Cultures
For single drug evaluation, an aliquot of the drug stock solution
was added to each 96 well plate containing 100 µL of 7-day
old stationary phase B. burgdorferi culture to obtain the desired
drug concentration. The plate was then sealed and was incubated
at 33◦C without shaking for 7 days. After incubation, the
viability of the residual viable cells was assessed using the SYBR
Green I/PI viability assay and conﬁrmed using epiﬂuorescence
microscopy (Feng et al., 2014b). Each sample was analyzed in
triplicate and the mean residual viable cells remaining were
calculated.
For assessing the activity of anthracycline compounds and
daptomycin and mitomycin C in combination with current
Lyme antibiotics against bioﬁlm-like structures, a 15-day old
B. burgdorferi stationary phase culture was used. Aliquots of
the drugs were added to 96 well plate containing 100 µL of
the 15-day old stationary phase B. burgdorferi culture which
was enriched in aggregated bioﬁlm-like structures to create a
ﬁnal drug concentration of 10 µg/mL for each drug. This drug
concentration was chosen as most drugs evaluated in this study
fell within or close to their Cmax values (maximum serum
concentration; Table 1). The plate was then sealed and was
incubated at 33◦C without shaking for 7 days, when the residual
viable cells remaining were measured using the SYBR Green I/PI
viability assay and conﬁrmed using epiﬂuorescence microscopy
as described (Feng et al., 2014b).
Subculture Study to Assess the Effect of
Drug Combination on the Biofilm-Like
Structures in B. burgdorferi Stationary
Phase Cultures
A 15-day old B. burgdorferi culture (500 µL of 1 × 107
spirochetes/mL) was exposed to the indicated drug combinations
in Eppendorf tubes, and incubated at 33◦C for 7 days without
shaking. After incubation, the bacteria were spun down and
washed with 1 mL fresh BSK-H medium. The cultures were
resuspended in 500 µL BSK-H medium, and a 50 µL aliquot
was used to inoculate a new tube of 1 mL fresh BSK-H
medium for subculture. The cultures were allowed to grow
for either 7 or 21 days, when they were evaluated for
regrowth with viable cells using the previously described SYBR
Green I/PI assay and epiﬂuorescence microscopy (Feng et al.,
2015a).
RESULTS AND DISCUSSION
Comparison of the Relative
Anti-Persister Activity of Daunomycin,
Doxorubicin, Daptomycin, and
Mitomycin C in Single Drug Exposure
Against Stationary Phase B. burgdorferi
Culture
Although daptomycin (Feng et al., 2014a), daunomycin (Feng
et al., 2015b), doxorubicin (Feng et al., 2015b), and mitomycin
C (Feng et al., 2015b; Sharma et al., 2015) were identiﬁed
to have high activity against B. burgdorferi persisters, their
relative activities have not been compared under the same
conditions. To do so, we compared them for their activity
against the same 7-day old B. burgdorferi stationary phase
culture at the same concentrations (5, 10, and 20 µM), using
SYBR Green I/PI viability stain followed by epiﬂuorescence
microscopy. The anthracycline drug daunomycin was shown
to have the highest activity against the stationary phase
cultures even at the lowest concentration (5 µM) with a
dose-dependent increase in killing activity resulting in a
near total clearance of bacteria at the highest concentration
(20 µM) as shown by mostly red (dead) cells and dispersed,
smaller aggregated microcolony size, revealed by the SYBR
Green I/PI viability assay (Figure 1, Table 1). Daptomycin
was the second most active drug against the B. burgdorferi
stationary phase culture, followed by doxorubicin (Figure 1,
Table 1). Mitomycin C was the least active drug among the
four persister-active drugs, and even at 20 µM had poor
TABLE 1 | Relative activity of daunomycin, daptomycin, doxorubicin, and
mitomycin C on a 7-day old B. burgdorferi stationary phase culturea.
Drugs 0 µM 5 µM 10 µM 20 µM Cmax
Daunomycin 89% 60% 50% 20% 30.2 µg/mL
(57 µM)
Daptomycin 89% 80% 60% 38% 57.8–93.9 µg/mL
(36–58 µM)
Doxorubicin 89% 88% 66% 50% 4.12–8.34 µg/mL
(7.6–15.3 µM)
Mitomycin C 89% 88% 85% 77% 2.4 µg/mL (7.2 µM)
aA 7 days old stationary phase culture of B. burgdorferi was treated with the
indicated drugs at different concentrations (0, 5, 10, and 20 µM) for 7 days.
Residual viability of B. burgdorferi after the antibiotic treatment was determined
using the SYBR Green I/PI viability assay followed by epifluorescence microscopy
and calculation of the percentage of green (viable) cells over red (dead) cells as
described (Feng et al., 2014a). Viabilities are the average of three replicates.
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FIGURE 1 | Comparison of anti-persister activity of daunomycin,
doxorubicin, daptomycin, and mitomycin C. A 7-day old B. burgdorferi
stationary phase culture containing aggregated microcolonies was incubated
for 7 days with daptomycin (Dap), daunomycin (Dau), doxorubicin (DoxR), or
mitomycin C (MitC) at the same drug concentrations of 5, 10, or 20 µM,
respectively, followed by viability assessment using the SYBR Green I/PI assay.
Representative images were taken using epifluorescence microscopy at 400×
magnification. Green cells indicate live cells while red cells indicate dead cells.
activity against the aggregated bioﬁlm-like microcolony form
of B. burgdorferi persisters, as shown by mostly green (live)
microcolonies remaining after the drug treatment for 7 days
(Figure 1).
Doxorubicin was less active than daunomycin as shown
by higher percentage of viable cells remaining after drug
exposure (Table 1) despite their both belonging to the same
anthracycline class. These results could be explained by structural
diﬀerences between those compounds (Figure 2A). Doxorubicin
possesses a hydroxyl group as opposed to a methyl group in
the corresponding position of daunomycin, with the remainder
of the anthracycline structure being identical. Interestingly,
although doxorubicin and daunomycin both have orange-red
color in solution (Figure 2B), we found daunomycin visibly
stained the B. burgdorferi cells red as seen in the red cell
pellet while doxorubicin only stained the cells rather faintly
(Figure 2C). This ﬁnding suggests that daunomycin may cross
the B. burgdorferi cell membrane more eﬃciently to accumulate
in the cell while doxorubicin may have poor ability to enter or
accumulate in B. burgdorferi cells.
Comparison of the Relative
Anti-Persister Activity of Daunomycin,
Daptomycin, Doxorubicin, and
Mitomycin C in Drug Combinations
Using SYBR Green I/PI Viability Assay
Both two-drug combinations doxycycline + cefuroxime and
doxycycline + cefoperazone showed poor activity against the 15-
day old stationary phase culture, with 67% residual viable (green)
cells remaining in comparison to 79% viable cells in the drug-free
control (Figure 3, Table 2). Consistent with the single drug
exposure experiment (Figure 1), daunomycin, doxorubicin
and daptomycin when added to the drug combination
doxycycline + cefuroxime had a high anti-persister activity
as seen by 12, 18, and 30% viable cells remaining (Table 2) as
well as mostly red (dead) cells after treatment (Figure 3). In
contrast, when mitomycin C was added to the drug combination
doxycycline + cefuroxime, the anti-persister activity of these
compounds was moderately increased as shown by 45% residual
viable cells remaining (Table 2), but more green (live) cells were
seen with the mitomycin C drug combination than with the
daunomycin or daptomycin drug combination (Figure 3).
Subculture Study to Assess the Relative
Anti-Persister Activity of Daunomycin,
Daptomycin, and Mitomycin C in Drug
Combinations
To validate the activity of these drug combinations, samples of
the above drug-treated cultures were subjected to subculture
after removal of the drugs by washing followed by incubation
in fresh BSK medium for 7 or 21 days. A lack of visible
regrowth when measured by microscopy suggests that few
to no viable cells remain after drug treatment, while visible
regrowth of the culture indicates the presence of viable
cells after drug treatment. The addition of daunomycin
or daptomycin to the doxycycline + cefuroxime drug
combination showed no visible regrowth after 7 and 21 days,
suggesting no viable B. burgdorferi organisms were left after
the treatment (Figure 4). Despite the high anti-persister
activity of doxorubicin + doxycycline + cefuroxime in the
microscopic analysis (Figure 3), with only 18% residual
viable cells after treatment (Table 2), this triple drug
combination was unable to prevent bacterial regrowth at
either 7 or 21 days subculture, indicating it is not as active
as daunomycin or daptomycin (Table 2, Figure 4). However,
doxorubicin + doxycycline + cefuroxime was more active
than mitomycin C + doxycycline + cefuroxime as shown by
less regrowth than the latter combination (Figure 4). This is
consistent with the single drug data where doxorubicin was more
active than mitomycin C (Figure 1).
The discrepancy in the activity of doxorubicin in
epiﬂuorescence microscopy based viability analysis and
subculture study was noted in our previous studies (Feng
et al., 2015a,b). This is due to the red orange color of the
anthracycline drug doxorubicin, which stains the cells red
and could give false impression of a high killing activity.
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FIGURE 2 | Differences in structures of daunomycin and doxorubicin and their ability to accumulate in B. burgdorferi. (A) Chemical structures of
daunomycin and doxorubicin. Red box shows the difference between the structures of daunomycin (methyl group) and doxorubicin (hydroxyl group).
(B) Daunomycin and doxorubicin show the same orange–red color at 10 mM solution. (C) Cell pellets of 7-day old B. burgdorferi treated with 10 µM daunomycin
(left-side tube) 10 µM doxorubicin (right-side tube) for 7 days, where daunomycin stained B. burgdorferi red while doxorubicin hardly stained the organism.
FIGURE 3 | Comparison of the activity of daunomycin, daptomycin, and mitomycin C in combination with currently used Lyme antibiotics. A 15-day
old B. burgdorferi stationary phase culture was incubated with the indicated drug combinations at a final concentration of 10 µg/mL for each antibiotic for 7 days
followed by SYBR Green I/PI stain and epifluorescence microscopy. Abbreviations: Dox, doxycycline; CefU, cefuroxime; CefP, cefoperazone; Dap, daptomycin; MitC,
mitomycin C; DoxR, doxorubicin; Dau, daunomycin.
However, subculture studies were able to show the inability
of doxorubicin + doxycycline + cefuroxime to eradicate the
microcolony form of B. burgdorferi persisters as shown by
regrowth after subculture. Thus, the subculture study is crucial
in validating the results of other forms of viability assays such as
SYBR Green I/PI assay in persister drug evaluations.
When mitomycin C was added to doxycycline + cefuroxime
combination treated B. burgdorferi stationary phase culture, there
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TABLE 2 | Viability of stationary phase B. burgdorferi after antibiotic
treatmenta assessed by direct SYBR Green I/PI viability assay and
subculture.
Drugs Residual
viable cellsb
Number of
spirochetes after
7 days subculture
Number of
spirochetes after
21 days subculture
Drug-free control 79% 6 × 106 2 × 107
Dox + Cefu 67% 1 × 106 1 × 107
Dox + Cefp 67% 9 × 105 1 × 107
Dox + Cefu + MitC 45% 0c 1 × 106
Dox + Cefu + DoxR 18% 4 × 105 8 × 105
Dox + Cefu + Dap 30% 0c 0c
Dox + Cefp + Dap 29% 0c 0c
Dox + Cefu + Dau 12% 0c 0c
aA 15-day old stationary phase B. burgdorferi culture (1 × 107 spirochetes) was
treated with 10 µg/mL of each antibiotic for 7 days. After treatment, 50 µL of the
washed bacteria were inoculated into 1 mL fresh BSK-H medium and cultured
for 7 or 21 days, when any possible regrowth was assessed by SYBR Green
I/PI staining followed by epifluorescence microscopy. bResidual viable cells after
7 days antibiotic treatment were calculated using epifluorescence microscopy as
previously described (Feng et al., 2014a). cValues are below the limit of detection
of <1 × 105 by microscopy.
was no regrowth at 7 days, but visible spirochetal regrowth
occurred after 21 days subculture (Figure 4). This ﬁnding
suggests that the addition of mitomycin C to the commonly
used Lyme antibiotics doxycycline + cefuroxime is not as
active as the addition of daunomycin or daptomycin, but is
more active than doxorubicin. Furthermore, this result indicates
that 7 days subculture is not suﬃcient to reveal the small
number of residual bacteria remaining after drug treatment
and that a prolonged incubation to 21 days is needed to
demonstrate the small numbers of viable bacteria for more
reliable evaluation of drug combinations against B. burgdorferi
persisters.
In a recent study, mitomycin C was shown to be more
active than daptomycin and to eradicate all B. burgdorferi
persisters (Sharma et al., 2015). This is in contrast to the
results of this study which found daptomycin to have higher
anti-persister activity than mitomycin C in both single drug
exposure (Table 1, Figure 1) and drug combination studies
(Figures 3 and 4). Several possibilities exist to explain the
discrepancy. First, we used older 7 and 15 days stationary
phase cultures containing an increased number of persisters and
bioﬁlm-like microcolonies previously shown to have increased
tolerance to antibiotics (Feng et al., 2015a), while the other
study used a younger culture of 5 days (Sharma et al., 2015),
which would have more growing cells and fewer persister cells.
The diﬀerence in persister numbers in these cultures would
result in the bacteria in the younger culture of 5 days being
more easily killed by mitomycin C but not by daptomycin.
Indeed, daptomycin is known to have relatively high MIC
(12.5–25 mg/mL) for growing spirochetes despite its high
activity against B. burgdorferi persisters (Feng et al., 2014a),
and this may also explain why daptomycin had limited activity
in that study as a younger culture was used (Sharma et al.,
2015). The use of a younger culture in the other study that
contained mainly growing spirochetes is also consistent with
their ﬁnding that the 5-day old culture was readily killed
by even amoxicillin and ceftriaxone (Sharma et al., 2015),
which are known to kill mainly growing bacteria. Second, we
used diﬀerent viability assays. In this study, we used SYBR
Green I/PI viability stain along with microscopy and subculture
in liquid medium to assess the viability of residual bacteria
after drug treatment. In contrast, the other study used colony
forming unit (CFU) assay on solid agar to determine the
viable bacteria after drug exposure (Sharma et al., 2015). Based
on studies with other bacteria like M. tuberculosis (Dhillon
et al., 2004), the CFU assay favors the detection of more
viable organisms and is less sensitive than culture in liquid
medium which can detect small numbers of viable cells which
may not grow on solid medium after drug exposure. Third,
we used BSK-H medium, which is richer than the BSK-
II medium used by the other study (Sharma et al., 2015),
FIGURE 4 | Subculture (21 days) of 15-day old B. burgdorferi stationary phase culture treated with different drug combinations. The 15-day old B.
burgdorferi culture was incubated with the indicated drug combinations at a final concentration of 10 g/mL for each antibiotic for 7 days followed by washing and
resuspension of cells in fresh BSK medium and subcultured for 21 days. The viability of the subculture was examined by SYBR Green I/PI viability assay and
epifluorescence microscopy (400 magnification). NG, no growth.
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which might have also contributed to the higher activity of
mitomycin C than daptomycin in that study (Sharma et al., 2015).
Cefuroxime (Ceftin) Could Replace
Cefoperazone in the
Daptomycin + Doxycycline Combination
to Completely Eradicate Biofilm-Like
Structures
In our previous drug combination study, we found that
daptomycin + doxycycline + cefoperazone was able to
completely eradicate the most resistant aggregated bioﬁlm-
like microcolonies (Feng et al., 2015a). However, since
cefoperazone is not available in the US, we replaced it
with the current Lyme antibiotic cefuroxime (Ceftin) in the
daptomycin + doxycycline combination and found they had
equivalent activity as shown by the same 30% residual viable
cells after antibiotic treatment using SYBR Green I/PI viability
stain and microscopy (Figure 3, Table 2). In subculture
studies, we found replacement of cefoperazone with cefuroxime
(Ceftin) in the daptomycin + doxycycline combination similarly
resulted in complete eradication of the bioﬁlm-like structures
as shown by lack of any regrowth in 7 and 21 days subcultures
(Figure 4).
Cefuroxime and cefoperazone, which are second and
third generation cephalosporins, respectively, function as
a highly penetrative beta-lactam antibiotic by disrupting
the bacterial cell wall biosynthesis (Barriere and Flaherty,
1984). Despite being reported as the best beta-lactam
antibiotic in the 7-day stationary phase persister model
(Feng et al., 2014a), cefoperazone did not give any
advantage over the use of the commonly prescribed Lyme
antibiotic cefuroxime (Ceftin) in the context of drug
combination with daptomycin + doxycycline (Figures 3
and 4). This data suggests that replacing cefoperazone
with the commonly used cefuroxime (Ceftin) will maintain
comparable eﬃcacy against the bioﬁlm-like microcolony form
of B. burgdorferi persisters in the drug combination with
daptomycin + doxycycline.
In this study, we were able to conﬁrm our previous
observations of the high anti-persister activity of daptomycin
(Feng et al., 2014a, 2015a) and daunomycin (Feng et al., 2015b)
alone and in drug combination with doxycycline + cefuroxime.It
is worth noting that the high anti-persister activity of daptomycin
and the anthracycline antibiotic daunomycin is due to the unique
mechanisms of action through disruption of cell membrane
and damage of DNA, respectively (Feng et al., 2014a, 2015b).
These observations suggest that bacterial membranes and
DNA integrity are important targets for bacterial persister
drugs. The complete eradication of bioﬁlm-like structures
of B. burgdorferi by daunomycin or daptomycin in drug
combination with doxycycline + cefuroxime, again supports
the Yin–Yang treatment principle of combining drugs that
target growing bacteria (Yang; with doxycycline + cefuroxime)
and drugs like daunomycin or daptomycin that target non-
growing persisters (Yin) for more eﬀective treatment of persistent
infections (Zhang, 2014). This strategy may be generally useful
for treatment of persistent infections including bioﬁlm infections,
which cannot be eradicated by a single drug alone. Future studies
are needed to validate this principle.
Although our ﬁndings that daunomycin or daptomycin
plus doxycycline + cefuroxime could completely eradicate
the bioﬁlm-like structures are encouraging, they are in vitro
studies and have limitations and cannot be equated to the
clinical situation. Moreover, daunomycin and daptomycin are
intravenous drugs and not convenient to administer. Future
studies to develop oral regimens as eﬀective as the above
combinations are needed for more convenient administration.
In addition, the toxicity associated with the anticancer drug
daunomycin calls for caution with its use in clinical settings.
Further in vivo animal studies are needed to validate the highly
active drug combinations identiﬁed in this study before they can
be used for patient treatment in the clinic.
CONCLUSION
In summary, we found that daunomycin and daptomycin
were more active against B. burgdorferi bioﬁlm-like
structures than mitomycin C and doxorubicin in single drug
comparisons as well as in drug combinations. Daunomycin
or daptomycin when added to doxycycline + cefuroxime
completely eradicated the bioﬁlm-like structures, while the
two drug combination doxycycline + cefuroxime alone or
mitomycin C and doxorubicin when added to the above
combination failed to do so. Additionally, we showed
that cefuroxime (Ceftin) could replace cefoperazone in the
daptomycin + doxycycline combination and caused complete
eradication of the bioﬁlm-like structures. Future studies are
needed to evaluate these promising drug combinations in vivo
in animal models, and if promising, in patients. Our ﬁndings
may have implications for improved treatment of Lyme
disease.
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